Constellation Pharmaceuticals (CNST) released positive preliminary results from its phase 2 study using CPI-0610 as a second-line therapy for patients with myelofibrosis. These results prove that the drug works in treating this patient population, but more important than that, it shows that the company's epigenetics platform approach can achieve efficacy. Updated data from this phase 2 study will be revealed at an upcoming oral presentation at the December 2019 ASH medical conference. It was also announced that the very same day updated data will be revealed. That is, management will host a webcast